Global Markets Direct’s, ‘Abdominal obesity – Pipeline Review, H1 2015′, provides an overview of the Abdominal obesity’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Abdominal obesity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Abdominal obesity and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Abdominal obesity
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Abdominal obesity and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Abdominal obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Abdominal obesity pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Abdominal obesity
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Abdominal obesity pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Abdominal Obesity Overview 6
Therapeutics Development 7
Pipeline Products for Abdominal Obesity - Overview 7
Pipeline Products for Abdominal Obesity - Comparative Analysis 8
Abdominal Obesity - Therapeutics under Development by Companies 9
Abdominal Obesity - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Abdominal Obesity - Products under Development by Companies 13
Abdominal Obesity - Companies Involved in Therapeutics Development 14
Aileron Therapeutics, Inc. 14
Genfit SA 15
Neothetics, Inc. 16
Zafgen Inc. 17
Abdominal Obesity - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
(salmeterol xinafoate + fluticasone propionate) - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ALRN-5281 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
elafibranor - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
salmeterol xinafoate - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ZGN-839 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Abdominal Obesity - Recent Pipeline Updates 38
Abdominal Obesity - Dormant Projects 45
Abdominal Obesity - Discontinued Products 46
Abdominal Obesity - Product Development Milestones 47
Featured News & Press Releases 47
Apr 13, 2015: Neothetics Initiates Pivotal Phase 3 Clinical Trials for LIPO-202, the First Non-Invasive Injectable Drug Candidate for Reduction of Subcutaneous Abdominal Fat 47
Mar 23, 2015: Neothetics Initiates Study to Evaluate Safety of Retreatment With LIPO-202 for Body Contouring 47
Feb 12, 2015: Leading Aesthetic Physicians Join Neothetics' Newly Formed Corporate Advisory Board 48
Sep 30, 2013: Lithera Reports Positive Clinical Study Results From Its Phase 2b RESET Trial for LIPO-202, a Novel Treatment for Abdominal Body Contouring 49
May 07, 2013: Aileron Therapeutics Successfully Completes Stapled Peptide Clinical Trial 49
Apr 02, 2013: Lithera Receives Patent From USPTO Protecting Methods Of Use And Formulations For LIPO-202 50
Mar 12, 2013: Lithera Initiates Phase IIb Clinical Trial Of LIPO-202 Targeting Aesthetic Reduction Of Subcutaneous Abdominal Fat 51
Feb 26, 2013: Aileron Therapeutics To Highlight Stapled Peptide Pipeline At 2013 AsiaTIDES Meeting 51
Sep 06, 2012: Aileron Therapeutics Unveils New Therapeutic Drug Program; Appoints Hubert C Chen As Vice President of Clinical Development 52
Sep 06, 2011: GENFIT Publishes GFT505 Clinical Trial Results In Diabetes Care 52
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55

List of Tables

Number of Products under Development for Abdominal Obesity, H1 2015 7
Number of Products under Development for Abdominal Obesity - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Abdominal Obesity - Pipeline by Aileron Therapeutics, Inc., H1 2015 14
Abdominal Obesity - Pipeline by Genfit SA, H1 2015 15
Abdominal Obesity - Pipeline by Neothetics, Inc. , H1 2015 16
Abdominal Obesity - Pipeline by Zafgen Inc., H1 2015 17
Assessment by Monotherapy Products, H1 2015 18
Assessment by Combination Products, H1 2015 19
Number of Products by Stage and Target, H1 2015 21
Number of Products by Stage and Mechanism of Action, H1 2015 23
Number of Products by Stage and Route of Administration, H1 2015 25
Number of Products by Stage and Molecule Type, H1 2015 27
Abdominal Obesity Therapeutics - Recent Pipeline Updates, H1 2015 38
Abdominal Obesity - Dormant Projects, H1 2015 45
Abdominal Obesity - Discontinued Products, H1 2015 46

List of Figures

Number of Products under Development for Abdominal Obesity, H1 2015 7
Number of Products under Development for Abdominal Obesity - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 11
Assessment by Monotherapy Products, H1 2015 18
Number of Products by Top 10 Targets, H1 2015 20
Number of Products by Stage and Top 10 Targets, H1 2015 20
Number of Products by Top 10 Mechanism of Actions, H1 2015 22
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 22
Number of Products by Top 10 Routes of Administration, H1 2015 24
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 24
Number of Products by Top 10 Molecule Types, H1 2015 26
Number of Products by Stage and Top 10 Molecule Types, H1 2015 26